PCI BIOTECH HOLDING ASA: årsregnskap 2023 vs 2022
Shrank 37% on revenue, returned to profit, cash halved-plus
approved 2024-05-24; registry 2024-06-18; journal 2024 473076
Summary
What changed
Comparing Årsregnskap 2023 with 2022 for PCI BIOTECH HOLDING ASA. Revenue 4.75m NOK → 2.99m NOK (-37.1%). Net result -467.24m NOK → +435.0k NOK. Equity 76.03m NOK → 78.42m NOK.
On the constructive side: operating result improved; turned profitable; equity strengthened. Pressures included: revenue fell; cash fell.
Also worth watching: paid-in equity reduced; book investments changed. All figures are taken from the published annual accounts for PCI BIOTECH HOLDING ASA.
At a glance
Scorecard
What improved
-
↑
Operating result improved
Operating result -5.22m NOK → -4.64m NOK (op. margin -109.9% → -155.1%). Calculated
-
↑
Turned profitable
Net result flipped from a loss of 467.24m NOK to a profit of 435.0k NOK. Calculated
-
↑
Equity strengthened
Book equity 76.03m NOK → 78.42m NOK (equity ratio 98.5% → 98.9%). Calculated
What deteriorated
-
↓
Revenue fell
Operating income / revenue moved from 4.75m NOK to 2.99m NOK (-37.1% YoY). Calculated
-
↓
Cash fell
Bank deposits 628.0k NOK → 56.0k NOK (-91.1% YoY). Calculated
Things to notice
-
·
Paid-in equity reduced
Paid-in equity fell 111.98m NOK → 1.12m NOK — check capital reduction, conversion, or reclassification. Interpretation
-
·
Book investments changed
Investment / intangible book value 69.16m NOK → 75.66m NOK. Reported fact